Brief: FDA Grants Orphan Drug Designation To Biostar Pharma's Utidelone
25/09/2025 16:28
Sept 25 (Reuters) - Biostar Pharma Inc: THE FDA GRANTED ORPHAN DRUG DESIGNATION TO BIOSTAR PHARMA'S UTIDELONE FOR THE TREATMENT OF PANCREATIC CANCER Source text: ID:nPnc3V5j5a Further company coverage: 2563.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beijing Biostar Pharmaceuticals
See all newsBrief: Beijing Biostar Pharmaceuticals To Issue 25 MLN New Shares At HK$4.00 Per Share
Brief: Beijing Biostar Pharmaceuticals Says Board Resolves To Repurchase H Shares In Open Market
Brief: Beijing Biostar Pharmaceuticals Posts FY Loss Attributable RMB131.4 Mln
Brief: FDA Grants Orphan Drug Designation To Biostar Pharma's Utidelone
Brief: Biostar Pharma Doses First Patients In Two Phase II/III Global Trials Of Utidelone Capsule (UTD2) For Cancer